Dr Sandya Subramaniam

Procedure Focus:

• Chemotherapy administration
• Targeted therapy and Immunotherapy administration
• Radiotherapy (IMRT, VMAT, 3D, 2D)
• Brachytherapy
• Stereotactic Radiosurgery, Stereotactic Body Radiation

Condition Treated:

• Prostate Cancer
• Breast Cancer
• Gastrointestinal Cancer
• Brain Cancer
• Head & Neck Cancer
• Sarcomas
• Lung Cancer
• Gynaecological Cancer

Memberships & Associations:

• Malaysian Oncological Society – Life Member
• College of Oncology, Academy of Medicine Malaysia – Life Member
• European Society for Medical Oncology – Member
• American Society of Clinical Oncology – Member
• Paediatric Radiation Oncology Society – Member
• Australian & New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) – Member
• European Society for Radiotherapy and Oncology – Member
• Kuala Lumpur Oncology Society – Office Bearer

Post Graduate Qualifications:

• Master of Clinical Oncology (University of Malaya)

Clinical Training:

• Fellowship in Advanced Radiation Oncology (Canada)

Awards:

Anugerah Perkhidmatan Cemerlang, Ministry of Health Malaysia 2016

Anugerah Perkhidmatan Cemerlang, Ministry of Health Malaysia 2023

Special Privileges:

Advanced Radiotherapy - SRS/GK, Brachytherapy, SBRT

Medical Training:

Universiti Malaysia Sarawak - Doctor of Medicine (MD)

Main Hospital:

ParkCity Medical Centre - PMC

Media / Publications:

• Potential of E-Learning Interventions and Artificial Intelligence–Assisted Contouring Skills in Radiotherapy: The ELAISA Study
• Prognostic Factors for Local Recurrence and Overall Survival in Nasopharyngeal Carcinoma in Hospital Kuala Lumpur
• An Overview of Pazopanib in Metastatic Renal Cell Carcinoma in Ministry of Health Malaysia – A Multicentre Experience – Poster Presentation at ASCOMOS 2017 and ESMO Asia 2017
• Primary Extragonadal Germ Cell Tumour of the Liver – Poster Presentation at ASCOMOS 2019
• Neutrophil Lymphocyte Ratio (NLR) Kinetics as a Biomarker of Treatment Response and Outcome – Poster Presentation at ASCOMOS 2019
• Neutrophil Lymphocyte Ratio and Platelet Lymphocyte Ratio as a Prognostic Factor in Locally Advanced Lung Cancer – Poster Presentation European Lung Cancer Congress 2021
• Principal investigator for “A Prospective Cohort Study of the Safety and Efficacy of Intraoperative Radiotherapy in Locally Advanced and Recurrent Rectal Cancer: A University of Malaya Medical Centre Experience.7
• Principal Investigator for “Randomized Phase III study of MK-7684A plus concurrent chemoradiotherapy (cCRT) followed by MK-7684A vs cCRT followed by Durvalumab for unresectable, locally advanced, stage III non-small cell lung cancer: KEYVIBE-006.
• Principal Investigator for “CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy & Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer & an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence.
• Chief Scientific Investigator for “ELAISA: Benefit of AI-assisted organ-at-risk contouring in head and neck cancer: A global randomized study.” Abstract presented in ESTRO 2023, published in JCO Global Oncology 5 Sept 2024.
• Supervisor, Co-Investigator for “Real world outcomes of Stereotactic Body Radiation Therapy (SBRT) for Localized Prostate Cancer at 3 major cancer specialist centers in Malaysia.”
• Principal Investigator for “A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer (KLK2-PASenger).”